These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 6362357)

  • 21. Fluctuation test for two-stage mutations: application to gene amplification.
    Kimmel M; Axelrod DE
    Mutat Res; 1994 Apr; 306(1):45-60. PubMed ID: 7512202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mean field mutation dynamics and the continuous Luria-Delbrück distribution.
    Kashdan E; Pareschi L
    Math Biosci; 2012 Dec; 240(2):223-30. PubMed ID: 22929625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative genetic analysis of tumor progression.
    Ling V; Chambers AF; Harris JF; Hill RP
    Cancer Metastasis Rev; 1985; 4(2):173-92. PubMed ID: 3893685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accounting for plating efficiency when estimating spontaneous mutation rates.
    Jones ME
    Mutat Res; 1993 Oct; 292(2):187-9. PubMed ID: 7692255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interval between methotrexate and leucovorin determines the efficacy of 5-fluorouracil modulation in vitro and in vivo.
    van der Wilt CL; de Jong M; Braakhuis BJ; Pinedo HM; Peters GJ
    Adv Exp Med Biol; 1993; 338():609-12. PubMed ID: 8304191
    [No Abstract]   [Full Text] [Related]  

  • 26. Improved inference of mutation rates: I. An integral representation for the Luria-Delbrück distribution.
    Kepler TB; Oprea M
    Theor Popul Biol; 2001 Feb; 59(1):41-8. PubMed ID: 11243927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1995; 12(1):55-69. PubMed ID: 7594878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synchronization with phase-specific agents in leukemia and correlation with clinical response to chemotherapy.
    Vogler WR; Kremer WB; Knospe WH; Omura GA; Tornyos K
    Cancer Treat Rep; 1976 Dec; 60(12):1845-59. PubMed ID: 1026339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-random acquisition of ethionine resistance by Chinese hamster fibroblasts. Appendix: acquisition of thermoresistance.
    Hill M; Hillova J
    Biomed Pharmacother; 1986; 40(1):11-9. PubMed ID: 3708113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An experimental solution for the Luria-Delbrück fluctuation problem in measuring hypermutation rates.
    Bachl J; Dessing M; Olsson C; von Borstel RC; Steinberg C
    Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6847-9. PubMed ID: 10359801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The historical development of cancer chemotherapy.
    Burchenal JH
    Semin Oncol; 1977 Jun; 4(2):135-46. PubMed ID: 327552
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanisms of drug resistance in human leukemia.
    Bertino JR; Srimatkandada S; Carman MD; Mini E; Jastreboff M; Moroson BA; Dube SK
    Haematol Blood Transfus; 1985; 29():90-5. PubMed ID: 4029741
    [No Abstract]   [Full Text] [Related]  

  • 33. A note on efficient estimation of mutation rates using Luria-Delbrück fluctuation analysis.
    Koziol JA
    Mutat Res; 1991 Jul; 249(1):275-80. PubMed ID: 2067540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On Bartlett's formulation of the Luria-Delbrück mutation model.
    Zheng Q
    Math Biosci; 2008 Sep; 215(1):48-54. PubMed ID: 18590919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluctuation analysis: the probability distribution of the number of mutants under different conditions.
    Stewart FM; Gordon DM; Levin BR
    Genetics; 1990 Jan; 124(1):175-85. PubMed ID: 2307353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anticancer chemotherapy and its place in the treatment of cancer].
    Coninx P; Lachapelle F; Pirenne Y
    Rev Med Liege; 1971 May; 26(10):351-4. PubMed ID: 5562609
    [No Abstract]   [Full Text] [Related]  

  • 37. A mathematical model of drug resistance: heterogeneous tumors.
    Panetta JC
    Math Biosci; 1998 Jan; 147(1):41-61. PubMed ID: 9401351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methotrexate resistant cells as targets for selective chemotherapy.
    Bertino JR; Mini E; Sobrero A; Moroson BA; Love T; Jastreboff M; Carmen M; Srimatkandada S; Dube S
    Adv Enzyme Regul; 1985; 24():3-11. PubMed ID: 3915186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin and DNA repair in cancer chemotherapy.
    Zamble DB; Lippard SJ
    Trends Biochem Sci; 1995 Oct; 20(10):435-9. PubMed ID: 8533159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The number of neutral mutants in an expanding Luria-Delbrück population is approximately Fréchet.
    Frank SA
    F1000Res; 2022; 11():1254. PubMed ID: 36845325
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.